Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effectsin vitro

While the SARS-CoV-2 pandemic is hardly hitting the world, it is of extreme importance that significantin vitroobservations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 cells. This strongly suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.